08:30 hrs Registration & welcome coffee

09:00 hrs Introduction

Session 1: Updates from new studies: TDM in clinical practice

09.10 hrs Updates from two randomized controlled studies TODORA and ADDORA using TDM in clinical practice in patients with rheumatic diseases     

Drs. Sadaf Atiqi, MD Reade, the Netherlands

09.30 hrs TDM in IBD: Insights from Prospective Clinical Trials

Dr. Mark Löwenberg MD, Amsterdam UMC, the Netherlands

09.50 hrs TDM updates in dermatology

Dr. Teresa Tsakok, MD St John's Institute of Dermatology, King's College London, Guy's and St Thomas' NHS foundation United Kingdom

10.10 hrs Pharmacokinetic-guided dose reduction of emicizumab in congenital hemophilia A

Dr Corien Eckhardt MD, UMC Utrecht, the Netherlands 

10.30 hrs Updates from the SUPERNEXT study: personalised extended interval dosing of natalizumab in patients with multiple sclerosis

Drs Liza Gelissen MD, Amsterdam UMC, the Netherlands

10.50 hrs          Panel discussion

11.00 hrs          Coffee break

 Session 2: Developments in PK modelling in TDM

11.30 hrs Model-informed precision dosing in TDM of biologics

Drs Stefan van den Berg, Sanquin, the Netherlands

11.50 hrs Using artificial intelligence in TDM models

Drs Alexander Janssen, Amsterdam UMC, the Netherlands

12.10 hrs Clinical pharmacology of infliximab in pediatrics

Dr Tim Preijers, Erasmus MC, the Netherlands

12.30 hrs Panel discussion

 12.45 hrs Lunch

 Session 3: Implementation of TDM in clinical practice

 13.30 hrs Patient perspective in TDM of biologics

Drs Suzanne Anjie, MD AmsterdamUMC, the Netherlands and Drs Maureen Leeuw, Reade, the Netherlands

13.45 hrs How to implement home-monitoring

Dr Maja Bulatovic Calasan MD, UMC Utrecht and Dr. Anne Martens, PurSang Diagnostiek, the Netherlands

14.00 hrs Home-Based Self-Sampling in IBD Care

Dr Patrick van Rheenen, UMC Groningen, the Netherlands

14.15 hrs Implementation of home-monitoring of natalizumab in multiple sclerosis, ups and downs 

Dr. Zoé van Kempen, MD, Amsterdam UMC, the Netherlands

14.30 hrs Panel discussion

14.45 hrs Coffee break

Session 4: Future of TDM

15.15 hrs Update and future of TDM of biologics from Norway

Prof. Dr. Espen A Haavardsholm MD, University of Oslo/Diakonhjemmet Hospital, Norway

15.45 hrs The future of TDM of biologics in different fields: 5  minutes pitches followed by panel discussion

Overview Gastrointestinal field

Dr Mark Löwenberg, MD AmsterdamUMC, the Netherlands

Overview Rheumatology field  

Prof. Dr. Gert-Jan Wolbink, MD, Amsterdam UMC, the Netherlands

Overview Dermatology field  

Dr. Teresa Tsakok, St John's Institute of Dermatology, King's College London, Guy's and St Thomas' NHS foundation United Kingdom

Overview Neurology field  

Prof. Dr. Joep Killestein MD, AmsterdamUMC, the Netherlands

Overview Oncology field  

Dr. Dirk-Jan Moes, LUMC, the Netherlands

 16.45 hrs FAREWELL DRINKS and network reception